These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30777597)

  • 41. Topical chemotherapy of precancerous dermatoses.
    Rossman RE
    Tex Med; 1968 Aug; 64(8):59-60. PubMed ID: 5666211
    [No Abstract]   [Full Text] [Related]  

  • 42. Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum.
    Hamouda B; Jamila Z; Najet R; Slim T; Rafiaa N; Noureddine B; Ahmed EM; Mohamed F; Ridha KM; Abderrahman L
    J Am Acad Dermatol; 2001 Jun; 44(6):1054. PubMed ID: 11369927
    [No Abstract]   [Full Text] [Related]  

  • 43. Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer.
    Patel PA
    Anticancer Drugs; 2011 Apr; 22(4):311-6. PubMed ID: 21301320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Keratosis punctata palmaris et plantaris treated with topical fluorouracil.
    Yancovitz M; Pasternack FR; Ward KM; Grossman ME
    Arch Dermatol; 2006 Aug; 142(8):1074-6. PubMed ID: 16924069
    [No Abstract]   [Full Text] [Related]  

  • 45. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis.
    Jorizzo J; Stewart D; Bucko A; Davis SA; Espy P; Hino P; Rodriguez D; Savin R; Stough D; Furst K; Connolly M; Levy S
    Cutis; 2002 Dec; 70(6):335-9. PubMed ID: 12502122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical efficacy of 5-fluorouracil (5-FU) topical cream for treatment of cholesteatoma.
    Takahashi H; Funabiki K; Hasebe S; Fukuda-Yamamoto T; Kaieda S; Iwanaga T; Kumagami H; Takasaki K
    Auris Nasus Larynx; 2005 Dec; 32(4):353-7. PubMed ID: 16039816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spontaneous apparent clinical resolution with histologic persistence of a case of extramammary Paget's disease: response to topical 5-fluorouracil.
    Del Castillo LF; Garcia C; Schoendorff C; Garcia JF; Torres LM; Garcia Almagro D
    Cutis; 2000 May; 65(5):331-3. PubMed ID: 10826098
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.
    Richel O; Wieland U; de Vries HJ; Brockmeyer NH; van Noesel C; Potthoff A; Prins JM; Kreuter A
    Br J Dermatol; 2010 Dec; 163(6):1301-7. PubMed ID: 20716208
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial.
    Walker JL; Siegel JA; Sachar M; Pomerantz H; Chen SC; Swetter SM; Dellavalle RP; Stricklin GP; Qureshi AA; DiGiovanna JJ; Weinstock MA
    J Invest Dermatol; 2017 Jun; 137(6):1367-1370. PubMed ID: 28532759
    [No Abstract]   [Full Text] [Related]  

  • 50. Topical 5% 5-fluorouracil in the treatment of multifocal basal cell carcinoma of the face: A novel chemotherapeutic approach.
    Naik MP; Mehta A; Abrol S; Kumar S; Gupta VS
    Orbit; 2016 Dec; 35(6):352-354. PubMed ID: 27715359
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determinants of the therapeutic efficacy of thymidylate synthase inhibitors.
    Peters GJ; Kuiper CM; van Triest B; Backus H; van der Wilt CL; van Laar JA; Jansen G; van Groeningen CJ; Pinedo HM
    Adv Exp Med Biol; 1998; 431():699-704. PubMed ID: 9598155
    [No Abstract]   [Full Text] [Related]  

  • 52. [Topical therapy of superficial basalioma and senile keratoma with 5-fluorouracil].
    Trnka J
    Cesk Dermatol; 1971 Oct; 46(5):187-91. PubMed ID: 5121700
    [No Abstract]   [Full Text] [Related]  

  • 53. Treatment of Bowen's disease with topical 5-fluorouracil under occlusion.
    Fulton JE; Carter DM; Hurley HJ
    Arch Dermatol; 1968 Feb; 97(2):178-80. PubMed ID: 5636054
    [No Abstract]   [Full Text] [Related]  

  • 54. [Therapeutic results of 5-fluorouracil in multiple and unresectable facial carcinoma secondary to xeroderma pigmentosum].
    Boussen H; Zwik J; Mili-Boussen I; Rammeh N; Bouaouina N; Gritli S; el May A; Kammoun MR; Ouertani A; Ladgham A
    Therapie; 2001; 56(6):751-4. PubMed ID: 11878102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. X-ACT: an important step on an unfinished journey.
    Maughan T
    Ann Oncol; 2012 Jul; 23(7):1655-8. PubMed ID: 22517823
    [No Abstract]   [Full Text] [Related]  

  • 56. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents.
    Tanaka F; Fukuse T; Wada H; Fukushima M
    Curr Pharm Biotechnol; 2000 Sep; 1(2):137-64. PubMed ID: 11467334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis.
    Loven K; Stein L; Furst K; Levy S
    Clin Ther; 2002 Jun; 24(6):990-1000. PubMed ID: 12117087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach.
    Graham BD; Jetmore AB; Foote JE; Arnold LK
    Dis Colon Rectum; 2005 Mar; 48(3):444-50. PubMed ID: 15747068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topical treatment of Bowen's disease with 5-Fluorouracil.
    Bargman H; Hochman J
    J Cutan Med Surg; 2003; 7(2):101-5. PubMed ID: 12447619
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of Arsenic-Induced Bowen’s Disease With Topical 5-Fluorouracil.
    Verhave B; Goldberg M; Hashim P; Levitt J
    J Drugs Dermatol; 2019 May; 18(5):477-479. PubMed ID: 31141858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.